Abstract:In the current study, we employed, structural informatics, and molecular simulation-based methods to engineer OmoMyc, a c-Myc dominant negative protein, to design novel mutants that could abrogate the c-MYC-MAX complex in Renal Carcinoma (RC). Among the total 472 mutations, only six mutations A61Q, Q64E, Q64K, N77R, Q64E-N77R, and Q64K-N77R were reported to increase the binding affinity and subjected to subsequent analysis such as protein-protein docking. The docking results revealed that the predicted mutants improve the functionality of the OmoMyc by not only increasing the binding affinity but also vdW and electrostatic energy in each complex that consequently increase the binding of the engineered OmoMyc by establishing extra hydrogen bonds, salt-bridges, and non-bonded contacts. Molecular simulation revealed a more stable behavior by the mutant complexes in contrast to the native OmoMyc however structural perturbations were reported in the regions, DBD (DNA-binding domain), loop region, and minor deviations at CTD (C terminal domain). Moreover, the hydrogen bonding and binding free energy results further validated the promising activity of our predicted mutants of OmoMyc. The results for TBE (total binding energy) revealed that the for each complex the TBE was calculated to be −87.88 ± 0.16 kcal/mol (WT OmoMyc-MAX), −91.89 ± 0.21 kcal/mol (A61Q OmoMyc-MAX), −91.55 ± 0.20 kcal/mol (Q64E OmoMyc-MAX), −95.17 ± 0.24 kcal/mol (Q64K OmoMyc-MAX), −96.49 ± 0.22 kcal/mol (N77R OmoMyc-MAX), −97.76 ± 0.22 kcal/mol (Q64E-N77R OmoMyc-MAX), and −95.31 ± 0.20 kcal/mol (Q64K-N77R OmoMyc-MAX) respectively. The results for TBE revealed promising results that allow the mutants to competitively inhibit the c-Myc-MAX complex more swiftly. Additionally, the internal motion and energy landscape were altered. These findings provide important insights into the potential of the mutants of OmoMyc as a therapeutic candidate for cancer treatment, particularly renal carcinoma, and could pave the way for the development of more effective clinical versions of OmoMyc.

Computational insights into the differentiated binding affinities of Myc, Max, and Omomyc dimers to the E-boxes of DNA

Comparative analysis of compound NSC13728 as Omomyc homodimer stabilizer by molecular dynamics simulation and MM/GBSA free energy calculation

Elucidation of the structural determinants responsible for the specific formation of heterodimeric Mxd1/Max b-HLH-LZ and its binding to E-box sequences

Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma

Molecular dynamics simulation reveals DNA-specific recognition mechanism via c-Myb in pseudo-palindromic consensus of mim-1 promoter

Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription

Differential Effects of the Widely Expressed Dmax Splice Variant of Max on E-Box Vs Initiator Element-Mediated Regulation by C-Myc

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Structural Basis of the Bhlh Domains of MyoD-E47 Heterodimer

Complexes of HMO1 with DNA: Structure and Affinity

Parallel Automated Flow Synthesis of Covalent Protein Complexes That Can Inhibit MYC-Driven Transcription

Intrinsically Disordered Regions in the Transcription Factor MYC:MAX Modulate DNA Binding via Intramolecular Interactions

Crystal structure of the DNA-binding domain of Mbp1, a transcription factor important in cell-cycle control of DNA synthesis

Comparison of the Protein-Protein Interfaces in the P53-Dna Crystal Structures: Towards Elucidation of the Biological Interface.

The Formation and Characteristics of the I-Motif Structure Within the Promoter of the C-Myb Proto-Oncogene.

Dynamics and Inhibition of MLL1 CXXC Domain on DNA Revealed by Single-Molecule Quantification

Heterodimeric DNA Motif Synthesis and Validations

Towards multistage modelling of protein dynamics with monomeric Myc oncoprotein as an example

MD investigation on the binding of microphthalmia-associated transcription factor with DNA

Mechanism of Interaction Between the Transactivation Domain of N-MYC and the DNA-Binding Surface of TFIIIC5

Affinity of synthetic peptide fragments of MyoD for Id1 protein and their biological effects in several cancer cells.